Nan Fung Life Sciences
Hong Kong SARnanfung.com
Overview
Nan Fung Life Sciences (NFLS) is the global investment platform of the Nan Fung Group, a Hong Kong-based conglomerate. Founded in 2017, it focuses on the life sciences sector, making direct investments (via its Pivotal bioVenture Partners funds) and fund investments. Its investment scope covers the full spectrum of the industry, including therapeutics, medical devices, and diagnostics, across various development stages, with a presence in the US and Greater China.
Portfolio Companies
10
Website
nanfung.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Ablaze Pharmaceuticals | Nov 2021 | Series A | Co-investor |
| Fountain Therapeutics | Nov 2021 | Series A Extension | Co-investor |
| Engrail Therapeutics | Aug 2021 | Series A Extension | Lead |
| Arctic Vision | Mar 2021 | Series B | Co-investor |
| OncXerna Therapeutics, Inc. | Jan 2021 | Series B | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
